Corvus Pharmaceuticals to Host R&D Day Highlighting Role of Adenosine Pathway in Immuno-Oncology
July 06 2017 - 4:10PM
Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of novel immuno-oncology therapies, today
announced that it will host an R&D Day on Tuesday, July 11,
2017, in New York City and provide a live webcast starting at 9:00
a.m. ET.
The event will focus on the adenosine pathway in immuno-oncology
and its potential to address the limitations of existing agents.
Speakers will include:
- Jonathan D. Powell, M.D., Ph.D., of Johns
Hopkins University
- Lawrence Fong, M.D., of the University of
California, San Francisco
- Matthew Hellmann, M.D., of Memorial Sloan
Kettering Cancer Center
- Richard Miller, M.D., Corvus co-founder,
president and CEO
R&D Day Webcast and Conference Call
Details
Event Title: R&D Day Update – The Adenosine
Pathway: Extending the Reach of Cancer
ImmunotherapyDate: Tuesday, July 11,
2017Time: 9:00 a.m. – 12:00 p.m.
ETWebcast: The live webcast and slide presentation
can be accessed at
https://event.webcasts.com/starthere.jsp?ei=1137880
An archive of the webcast will be available in the Investors
section of the Company’s website for 30 days following the
event.
About Corvus Pharmaceuticals Corvus
Pharmaceuticals is a clinical-stage biopharmaceutical company
focused on the development and commercialization of small molecule
and antibody agents that target the immune system to treat patients
with cancer. These agents block or modify crucial immune
checkpoints and reprogram immune T-cells. Corvus’ lead product,
CPI-444, is a checkpoint inhibitor that is designed to disable a
tumor’s ability to subvert attack by the immune system by
inhibiting adenosine in the tumor microenvironment. CPI-444 is a
small molecule that is taken orally. CPI-444 is currently being
evaluated in a multicenter Phase 1/1b clinical trial in patients
with various solid tumors. This successive expansion cohort trial
is examining the activity of CPI-444 both as a single agent and in
combination with Genentech’s atezolizumab, an anti-PD-L1 antibody.
Corvus is conducting the trial with Genentech, a member of
the Roche Group, under a clinical trial collaboration the two
companies entered into in October 2015. For more information,
visit www.corvuspharma.com.
Tecentriq® (atezolizumab) is a registered trademark of
Genentech.
Corvus Contact:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
LLea@corvuspharma.com
Media Contact:
Megan McCormick
Pure Communications
+1-858-617-0774
mmccormick@purecommunications.com
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Apr 2024 to May 2024
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From May 2023 to May 2024